The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.
about
Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effectsHead-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa LIntermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependenceCannabinoid modulation of noradrenergic circuits: implications for psychiatric disordersEndocannabinoid-mediated synaptic plasticity and addiction-related behaviorInteraction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retentionMemory encoding in hippocampal ensembles is negatively influenced by cannabinoid CB1 receptorsEndocannabinoid signaling in the etiology and treatment of major depressive illness.Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling.Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choiceDepression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptorsModulation of the serotonin system by endocannabinoid signalingA review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research.Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.Advances in pharmacotherapy for tobacco dependence.A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.The endocannabinoid/endovanilloid system and depression.The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Ultrastructural evidence for synaptic contacts between cortical noradrenergic afferents and endocannabinoid-synthesizing post-synaptic neurons.Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report.A possible role for the endocannabinoid system in the neurobiology of depressionSupraspinal modulation of pain by cannabinoids: the role of GABA and glutamateCannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.Role of the serotonergic system in alcohol dependence: from animal models to clinics.Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in miceCB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area.Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.Changes in c-Fos Expression in the Forced Swimming Test: Common and Distinct Modulation in Rat Brain by Desipramine and Citalopram.The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction.Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortexRole of endocannabinoid signaling in anxiety and depression.Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnessesEndocannabinoid-mediated control of synaptic transmission.
P2860
Q24534868-0DAF678F-417E-4348-A325-5987829FC80DQ24595389-A27FA2AF-9699-4A35-8380-86335CB073F5Q24626361-C976C981-470E-4F60-89C1-CB711838C779Q24645054-865AF55B-3F16-4C2E-BDDF-7AE76772CA5BQ27001139-43065C5A-1C86-404F-A07C-2774F0CF2151Q29042501-6DAD08FE-AC84-4C21-A87D-C741766785CFQ30392035-0B320558-5AEF-4F89-BB35-7F479E0F0042Q30465050-45E79D84-4AD4-4422-B4CB-5BF2330C186EQ30687668-6D289C82-5455-48EF-B9F7-7C162C36FECBQ33865196-3034AE48-B1B3-43B8-A953-86F391A4F6F7Q34053352-54021BB6-1B69-4580-A16D-3853EECA7B7BQ34116825-0D99E921-07BD-466F-A4E9-3E51E5D038BFQ34167072-FD212325-DD57-449F-91A7-9836587684B4Q34264449-AC1EEC5C-3D9C-44E2-8FC3-A390C7C11C2AQ34273681-2DC52D53-A4DD-49CE-9386-3F9E01A05DC0Q34322083-ADC58B37-E667-4488-A002-3B37A13C4C24Q34502250-E6CBEC09-055F-42E3-9CAC-7AAC8D9482B3Q34567576-8534CE50-39D0-4DFB-8527-31965D18EC8BQ34626755-E3D1FF67-DF6B-4400-8686-805641A83FABQ34674584-9C9B44C1-0FD2-44E6-8F2B-BD37E3DDF426Q34798544-8A4CD860-BA8C-42B3-B9AE-7C8BB912E52AQ35121789-12003CC2-F47B-4B51-B2A3-F581C06F116AQ35532072-C4BE0970-6B1B-48B9-BC79-FEDD1C00FF2DQ35672654-A7B8C984-C4A2-44CD-AB16-51A0FDD280B3Q35972392-68283984-8FED-4612-A7FA-FB9EE6B02F1EQ36174333-6E65C4E3-7222-4378-B25A-5BD32415FC38Q36316074-780D2FB9-9330-46F6-9347-4C2FF831250DQ36358712-1CBDB3E7-4A10-4FA7-BA06-7FE770B86154Q36425951-A88EFA50-7853-4D48-A276-C5481F174C83Q36429331-6B6C0581-2EBE-4743-8FEA-D50F77E3CC3AQ36496715-E3326076-C634-413C-88BE-993F0E749903Q36712228-DDAE0A5C-536E-44BE-9EA3-022C5588C665Q36873051-404ED774-BB0D-4685-8C56-6A4639DBC678Q37001332-6BA3E9AD-B755-4B40-8A84-9C82A3352FCEQ37090099-2820C2B8-4EED-4D68-92D5-A36D17671D81Q37142233-015651F1-F734-4A1B-8904-519ECBC391A6Q37240007-5F550990-4A6D-4A09-B319-6CAB16BA7885Q37254797-8FEEE5A9-EC31-49E0-945D-BD80B0578AE1Q37279826-DCDA743B-67CC-4CE7-86A0-036AB4158DACQ37363621-04EE29FA-4AC9-41BC-8DB6-079FC2789165
P2860
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The CB1 receptor antagonist SR ...... tions for therapeutic actions.
@en
type
label
The CB1 receptor antagonist SR ...... tions for therapeutic actions.
@en
prefLabel
The CB1 receptor antagonist SR ...... tions for therapeutic actions.
@en
P2093
P2860
P356
P1476
The CB1 receptor antagonist SR ...... tions for therapeutic actions.
@en
P2093
Craig Salhoff
Eleni T Tzavara
Frank P Bymaster
George G Nomikos
Jeffrey M Witkin
Kenneth W Perry
Richard J Davis
P2860
P304
P356
10.1038/SJ.BJP.0705100
P407
P577
2003-02-01T00:00:00Z